Merck & Co. Inc. is farming out some of its cardiovascular discovery effort to privately held Canadian firm Xenon Pharmaceuticals Inc. in a deal that would bring in up to $94.5 million for the first therapeutic target and up to $89.5 million for each subsequent target that is sected for drug discovery. (BioWorld Today)